+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Neuropathic Pain Drug Market Research Report by Type, by Indication, by Diagnosis, by Distribution, by End User - Global Forecast to 2025 - Cumulative Impact of COVID-19

  • ID: 4968619
  • Report
  • June 2020
  • Region: Global
  • 202 pages
  • 360iResearch™
until Dec 31st 2020
1 of 3

Enquire about COVID-19 updates for this product.

Enquire Now
The Global Neuropathic Pain Drug Market to Grow USD 13,380.73 Million by 2025, at a CAGR of 8.72%


  • Biogen Idec Inc.
  • Depomed Inc.
  • Eli Lily and Company
  • GlaxoSmithKline PLC
  • Pfizer Inc.
  • Sanofi S.A.
  • MORE
The Global Neuropathic Pain Drug Market is expected to grow from USD 8,098.49 Million in 2019 to USD 13,380.73 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 8.72%.

Market Segmentation & Coverage:

This research report categorizes the Neuropathic Pain Drug to forecast the revenues and analyze the trends in each of the following sub-markets:

On the basis of Type, the Neuropathic Pain Drug Market is examined across Phantom Limb Pain, Post Herpetic Neuralgia, Post-traumatic Neuropathy, and Trigeminal Neuralgia.

On the basis of Treatment, the Neuropathic Pain Drug Market is examined across Antidepressant Drugs Type, Medication Type, Multimodal Therapy, and NSAIDs Type. The Antidepressant Drugs Type further studied across Serotonin Noradrenaline and Tricyclic Antidepressants. The NSAIDs Type further studied across Ibuprofen and Naproxen.

On the basis of Indication, the Neuropathic Pain Drug Market is examined across Diabetic Neuropathy and Spinal Stenosis.

On the basis of Diagnosis, the Neuropathic Pain Drug Market is examined across Blood Tests and Imaging Physical Examination. The Imaging Physical Examination further studied across CT, Electromyography, and MRI.

On the basis of Distribution, the Neuropathic Pain Drug Market is examined across Online Pharmacies and Retail Pharmacies & Drug Stores.

On the basis of End User, the Neuropathic Pain Drug Market is examined across Clinics and Hospitals.

On the basis of Geography, the Neuropathic Pain Drug Market is examined across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region is examined across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region is examined across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region is examined across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Company Usability Profiles:

The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Neuropathic Pain Drug Market including Baxter Healthcare Corporation, Biogen Idec Inc., Bristol-Myers Squibb and Company, Depomed Inc., Eli Lily and Company, GlaxoSmithKline PLC, Johnson & Johnson Services Inc., Pfizer Inc., and Sanofi S.A..

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Neuropathic Pain Drug Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Neuropathic Pain Drug Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Neuropathic Pain Drug Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Neuropathic Pain Drug Market?
4. What is the competitive strategic window for opportunities in the Global Neuropathic Pain Drug Market?
5. What are the technology trends and regulatory frameworks in the Global Neuropathic Pain Drug Market?
6. What are the modes and strategic moves considered suitable for entering the Global Neuropathic Pain Drug Market?
Note: Product cover images may vary from those shown
2 of 3


  • Biogen Idec Inc.
  • Depomed Inc.
  • Eli Lily and Company
  • GlaxoSmithKline PLC
  • Pfizer Inc.
  • Sanofi S.A.
  • MORE
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology
2.1. Research Process
2.1.1. Define: Research Objective
2.1.2. Determine: Research Design
2.1.3. Prepare: Research Instrument
2.1.4. Collect: Data Source
2.1.5. Analyze: Data Interpretation
2.1.6. Formulate: Data Verification
2.1.7. Publish: Research Report
2.1.8. Repeat: Report Update
2.2. Research Execution
2.2.1. Initiation: Research Process
2.2.2. Planning: Develop Research Plan
2.2.3. Execution: Conduct Research
2.2.4. Verification: Finding & Analysis
2.2.5. Publication: Research Report
2.3. Research Outcome
2.3.1. Competitive Strategic Window

3. Executive Summary
3.1. Market Outlook
3.2. Type Outlook
3.3. Treatment Outlook
3.4. Indication Outlook
3.5. Diagnosis Outlook
3.6. Distribution Outlook
3.7. End User Outlook
3.8. Geography Outlook
3.9. Competitor Outlook

4. Market Overview
4.1. Introduction
4.2. Neuropathic Pain Drug Market, By Geography

5. Market Dynamics
5.1. Introduction
5.1.1. Drivers
5.1.2. Restraints
5.1.3. Opportunities
5.1.4. Challenges

6. Market Insights
6.1. Porters Five Forces Analysis
6.1.1. Threat of New Entrants
6.1.2. Threat of Substitutes
6.1.3. Bargaining Power of Customers
6.1.4. Bargaining Power of Suppliers
6.1.5. Industry Rivalry
6.2. Cumulative Impact of COVID-19
6.3. Client Customizations

7. Global Neuropathic Pain Drug Market, By Type
7.1. Introduction
7.2. Phantom Limb Pain
7.3. Post Herpetic Neuralgia
7.4. Post-traumatic Neuropathy
7.5. Trigeminal Neuralgia

8. Global Neuropathic Pain Drug Market, By Treatment
8.1. Introduction
8.2. Antidepressant Drugs Type
8.2.1. Serotonin Noradrenaline
8.2.2. Tricyclic Antidepressants
8.3. Medication Type
8.4. Multimodal Therapy
8.5. NSAIDs Type
8.5.1. Ibuprofen
8.5.2. Naproxen

9. Global Neuropathic Pain Drug Market, By Indication
9.1. Introduction
9.2. Diabetic Neuropathy
9.3. Spinal Stenosis

10. Global Neuropathic Pain Drug Market, By Diagnosis
10.1. Introduction
10.2. Blood Tests
10.3. Imaging Physical Examination
10.3.1. CT
10.3.2. Electromyography
10.3.3. MRI

11. Global Neuropathic Pain Drug Market, By Distribution
11.1. Introduction
11.2. Online Pharmacies
11.3. Retail Pharmacies & Drug Stores

12. Global Neuropathic Pain Drug Market, By End User
12.1. Introduction
12.2. Clinics
12.3. Hospitals

13. Americas Neuropathic Pain Drug Market
13.1. Introduction
13.2. Argentina
13.3. Brazil
13.4. Canada
13.5. Mexico
13.6. United States

14. Asia-Pacific Neuropathic Pain Drug Market
14.1. Introduction
14.2. Australia
14.3. China
14.4. India
14.5. Indonesia
14.6. Japan
14.7. Malaysia
14.8. Philippines
14.9. South Korea
14.10. Thailand

15. Europe, Middle East & Africa Neuropathic Pain Drug Market
15.1. Introduction
15.2. France
15.3. Germany
15.4. Italy
15.5. Netherlands
15.6. Qatar
15.7. Russia
15.8. Saudi Arabia
15.9. South Africa
15.10. Spain
15.11. United Arab Emirates
15.12. United Kingdom

16. Competitive Landscape
16.1. FPNV Positioning Matrix
16.1.1. Quadrants
16.1.2. Business Strategy
16.1.3. Product Satisfaction
16.2. Market Ranking Analysis
16.3. Market Share Analysis
16.4. Competitive Scenario
16.4.1. Merger & Acquisition
16.4.2. Agreement, Collaboration & Partnership
16.4.3. New Product Launch & Enhancement
16.4.4. Investment & Funding

17. Company Usability Profiles
17.1. Baxter Healthcare Corporation
17.2. Biogen Idec Inc.
17.3. Bristol-Myers Squibb and Company
17.4. Depomed Inc.
17.5. Eli Lily and Company
17.6. GlaxoSmithKline PLC
17.7. Johnson & Johnson Services Inc.
17.8. Pfizer Inc.
17.9. Sanofi S.A.

18. Appendix
18.1. Discussion Guide
18.2. Edition Details
18.3. License Details
18.4. Pricing Details
Note: Product cover images may vary from those shown
3 of 3
  • Baxter Healthcare Corporation
  • Biogen Idec Inc.
  • Bristol-Myers Squibb and Company
  • Depomed Inc.
  • Eli Lily and Company
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services Inc.
  • Pfizer Inc.
  • Sanofi S.A.
Note: Product cover images may vary from those shown